[1]付妮娜,范婧晖,钟　慧.CA125，HE4和 MMP7联合检测在 I型和 II型上皮性卵巢癌患者诊断中的价值[J].现代检验医学杂志,2019,34(06):109-112.[doi:10.3969 ／ j.issn.1671-7414.2019.06.027]
　FU Ni-na,FAN Jing-hui,ZHONG Hui.Diagnostic Value of Combined Detection of CA125, HE4 and MMP7 in Type I and II Epithelial Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):109-112.[doi:10.3969 ／ j.issn.1671-7414.2019.06.027]
点击复制

CA125，HE4和 MMP7联合检测在 I型和 II型上皮性卵巢癌患者诊断中的价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年06期
页码:
109-112
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Diagnostic Value of Combined Detection of CA125, HE4 and MMP7 in Type I and II Epithelial Ovarian Cancer
文章编号:
1671-7414（2019）06-109-05
作者:
付妮娜1; 范婧晖1; 钟　慧2
（1. 宝鸡市妇幼保健院检验科，陕西宝鸡　721000；2. 陕西省核工业二一五医院妇科，陕西咸阳　712000）
Author(s):
FU Ni-na1;  FAN Jing-hui1;  ZHONG Hui2
（1. Department of Clinical Laboratory, Baoji Maternal and Child Health Hospital, Shaanxi Baoji 721000, China; 2. Department of Gynecology, Shaanxi Nuclear Industry 215 Hospital, Shaanxi Xianyan 712000, China）
关键词:
上皮性卵巢癌(EOC); 糖类抗原125(CA125); 人附睾蛋白4(HE4); 基质金属蛋白酶7(MMP7)
分类号:
R737.31；R730.43
DOI:
10.3969 ／ j.issn.1671-7414.2019.06.027
文献标志码:
A
摘要:
目的　探究糖类抗原125(CA125)、人附睾蛋白4(HE4) 和基质金属蛋白酶7(MMP7) 联合检测在I 型和II 型上 皮性卵巢癌患者诊断中的价值。方法　选取243 例上皮性卵巢癌患者为研究对象，采用酶联免疫吸附试验(ELISA) 测 定分析I，II 型上皮性卵巢癌(epithelial ovarian cancer，EOC) 患者中CA125，HE4 和MMP7 的浓度水平，分别评价 CA125，HE4 和MMP7 联合检测在I，II 型EOC，早晚期I，II 型EOC 和绝经前后I，II 型EOC 的诊断价值。结果　I， II 型EOC 中的CA125 均显著高于良性肿瘤组(P ＜ 0.001)。I，II 型EOC 中的HE4 均显著高于良性肿瘤组(P ＜ 0.001)， 相较于I 型EOC 中单一和多指标联合的AUC 值，II 型EOC 中多指标联合(CA125+HE4+MMP7) 的AUC 检测值较 高；早期I，II 型EOC 患者CA125 的M 值显著低于晚期(r = － 6.2，P =0.000)。早期I，II 型EOC 患者HE4 的M 值显 著低于晚期(r = － 4.314，P =0.002)，相较于早期I 型单一和多指标联合和II 型单一指标中的AUC 值，II 型EOC 晚期 患者中多指标联合(CA125+HE4+MMP7) 的AUC 检测值较高；相较于I，II 型EOC 患者与良性肿瘤组，多指标联合 (CA125+HE4+MMP7) 在绝经后EOC 患者的AUC 检测值较高。结论　CA125，HE4 和MMP7 联合标记物在II 型EOC 患者中的AUC 检测值较高。
Abstract:
Objective　To evaluate the diagnostic value of combined detection of CA125, HE4 and MMP7 in patients with type I and II epithelial ovarian cancer (EOC). Methods　A total of 243 patients with epithelial ovarian cancer were selected as research objects and enzyme linked immunosorbent assay (ELISA) was applied for analyzing the concentration levels of CA125，HE4 and MMP7 in patients with type I and II EOC, then evaluated the diagnostic value of combined detection of CA125, HE4 and MMP7 in patients with type I and II EOC, type I and II EOC at early and late stage, type I and II EOC before and after menopause respectively. Results　The concentration levels of CA125 in type I and II EOC were significantly higher than that in the benign tumor group (P ＜ 0.001), the concentration levels of HE4 in type I and II EOC were significantly higher than that in the benign tumor group (P ＜ 0.001), and the AUC value of combined indicators (CA125+HE4+MMP7) in type II EOC was higher than that of single and combined indicators in type I EOC. The M value of CA125 in early stage I and II EOC patients was significantly lower than that in late stage (r = － 6.2, P =0.000). The M value of HE4 in early stage I and II EOC patients was significantly lower than that in late stage (r = － 4.314，P =0.002), and the AUC value of combined indicators (CA125+HE4+MMP7) in late stage type II EOC patients was higher than that of single and combined indicators in type I EOC patients and single indicator in type II EOC patients. The AUC value of combined indicators (CA125+HE4+MMP7) in EOC patients after menopause was higher than that in type I and II EOC patients and benign tumor group. Conclusion　The AUC value of combined indicators (CA125+HE4+MMP7) in type II EOC patients was higher.

参考文献/References:

[1]　TAYLOR K N, ESKANDER R N. PARP inhibitors in epithelial ovarian cancer[J]. Recent Patents on Anti- Cancer Drug Discovery, 2018, 13(2):145-158.
[2]　CORRADO G, SALUTARI V, PALLUZZI E, et al. Optimizing treatment in recurrent epithelial ovarian cancer[J]. Expert Review of Anticancer Therapy, 2017, 17(12):1147-1158.
[3]　WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017, 41(5):3-14.
[4]　赵枰, 洪煜婧, 陈相, 等. 上皮性卵巢癌患者外周血 循环肿瘤细胞检测的临床意义[J]. 现代检验医学杂 志, 2017, 32(4):50-51,56. ZHAO Ping, HONG Yujing, CHEN Xiang, et al. Clinical significance of circulating tumor cells detection from peripheral blood of patients with epithelial ovarian cancer[J]. Journal of Modern Laboratory Medicine, 2017, 32(4):50-51,56.
[5]　SIDAWAY P. Ovarian cancer: Algorithm enables early detection[J]. Nature Reviews Clinical Oncology, 2017, 14(5):262.
[6]　TUNA M, JU Z, SMID M, et al. Prognostic relevance of acquired uniparental disomy in serous ovarian cancer[J]. Molecular Cancer, 2015, 14(1):29-31.
[7]　WU N Y, HUANG H S, CHAO T H , et al. progesterone prevents high-grade serous ovarian cancer by inducing necroptosis of p53-Defective fallopian tube epithelial cells[J]. Cell Reports, 2017, 18(11):2557-2565.
[8]　HARDWICK N R, FRANKEL P, RUEL C, et al. p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy[J]. Clinical Cancer Research, 2018, 24(6):1315-1325.
[9]　ELZEK M A, RODLAND K D. Proteomics of ovarian cancer: functional insights and clinical applications[J]. Cancer and Metastasis Reviews, 2015, 34(1):83-96.
[10] 李玲, 罗雅文, 何霞, 等. 子宫内膜癌患者BMI 与血 清HE4,CA125 联合检测的诊断价值[J]. 现代检验医 学杂志, 2018, 33(5):91-94. LI Ling, LUO Yawen, HE Xia, et al. Diagnostic value of combined detection of body mass index and serum HE4,CA125 in patients with endometrial carcinoma[J]. Journal of Modern Laboratory Medicine, 2018, 33(5):91-94.
[11] MANDERS D B, KISHORE H A, GAZDAR A F, et al. Dysregulation of fibulin-5 and matrix metalloproteases in epithelial ovarian cancer[J]. Oncotarget, 2018, 9(18):14251-14267.
[12] ABDALLA N, PIORKOWSKI R, BACHANEK M, et al. Does the risk of ovarian malignancy algorithm provide better diagnostic performance than HE4 and CA125 in the presurgical differentiation of adnexal tumors in polish women [J]. Disease Markers, 2018, 20(18):1-12.
[13] 牛艳昕, 王楠, 刘杰. 血清HE4, CA125, VEGF 联 合检测对卵巢癌诊断价值分析[J]. 医学研究杂志, 2016, 45(10):142-144,56. NIU Yanxin, WANG Nan, LIU Jie. Diagnostic value of combined detection of serum HE4, CA125 and VEGF in the diagnosis of ovarian Cancer [J]. Journal of Medical Research, 2016, 45(10):142-144,56.
[14] SEHOULI J, OLSCHEWSKI J, SCHOTTERS V, et al. Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube[J]. Annals of Oncology, 2013, 24(12):3024-3028.
[15] 李玉芳, 邬春霞, 郭端英. 卵巢上皮癌患者血清中 HE4 及 CA125 的水平及其与预后的关系[J]. 贵阳医 学院学报, 2014, 39(4):598-600. LI Yufang, WU Chunxia, GUO Duanying. Serum levels of E4 and CA125 in patients with ovarian epithelial carcinoma and their relationship with prognosis[J]. Journal of Guizhou Medical University, 2014, 39(4):598-600.
[16] 张平峰, 蔡军, 吴安涛. MMP-7 在肿瘤中的研究进 展[J]. 实用临床医学, 2014, 15(2):131-133. ZHANG Pingfeng, CAI Jun, WU Antao. Research progress of matrix metalloproteinase 7 in tumor[J]. Practical Clinical Medicine (Jiangxi), 2014, 15(2):131-133.
[17] LU D, KUHN E, BRISTOW R E, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer[J]. Gynecologic Oncology, 2011, 122(3):560-566.
[18] KIDDLE S J, SATTLECKER M, PROITSI P, et al. Candidate blood proteome markers of Alzheimer's disease onset and progression:a systematic review and replication study[J]. Journal of Alzheimers Disease Jad, 2014, 38(3):515-531.
[19] 邢瑞青, 吴永昌, 陈慧昱, 等. 血清CA125,HE4 及 ROMA 指数对卵巢癌诊断价值的临床研究[J]. 现代 检验医学杂志, 2016, 31(6):37-40,43. XING Ruiqiang, WU Yongchang, CHEN Huiyu, et al. Diagnostic value of serum CA125,HE4 and ROMA index in patients with ovarian cancer[J].Journal of Modern Laboratory Medicine, 2016, 31(6):37-40,43.
[20] 詹颉, 常宁宁, 李小侠, 等. CEA，AFP，CA125， CA199 和CA72-4 联合检测在鉴别卵巢良恶性疾病中 的应用价值[J]. 现代检验医学杂志, 2015, 30(5):50-52. ZHAN Jie, CHANG NingNing, LI Xiaoxia, et al. Clinical value of combined detection of CEA，AFP， CA125，CA199 and CA72-4 in the identification of ovarian benign and malignant disease[J]. Journal of Modern Laboratory Medicine, 2015, 30(5):50-52.

备注/Memo

备注/Memo:
基金项目：陕西省自然科学基金项目（2013JM4016）。 作者简介：付妮娜（1982 －），女，本科，主管检验师，研究方向：临床生化免疫，E-mail：baofunin@qq.com。 通讯作者：钟慧（1968 －），女，硕士，副主任医师，研究方向：妇科肿瘤基础与临床研究，E-mail:3220310835@qq.com 收稿日期：2019-01-04
更新日期/Last Update: 2019-12-25